XBIT vs. ETON, ATXS, AURA, PHAT, GLUE, ESPR, CADL, MBX, RGNX, and TSHA
Should you be buying XBiotech stock or one of its competitors? The main competitors of XBiotech include Eton Pharmaceuticals (ETON), Astria Therapeutics (ATXS), Aura Biosciences (AURA), Phathom Pharmaceuticals (PHAT), Monte Rosa Therapeutics (GLUE), Esperion Therapeutics (ESPR), Candel Therapeutics (CADL), MBX Biosciences (MBX), REGENXBIO (RGNX), and Taysha Gene Therapies (TSHA). These companies are all part of the "pharmaceutical products" industry.
XBiotech vs.
Eton Pharmaceuticals (NASDAQ:ETON) and XBiotech (NASDAQ:XBIT) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, profitability, dividends, valuation, community ranking, media sentiment, analyst recommendations and institutional ownership.
Eton Pharmaceuticals has a beta of 1.4, suggesting that its stock price is 40% more volatile than the S&P 500. Comparatively, XBiotech has a beta of 1.45, suggesting that its stock price is 45% more volatile than the S&P 500.
XBiotech has a net margin of 0.00% compared to Eton Pharmaceuticals' net margin of -15.81%. XBiotech's return on equity of -15.99% beat Eton Pharmaceuticals' return on equity.
27.9% of Eton Pharmaceuticals shares are held by institutional investors. Comparatively, 55.7% of XBiotech shares are held by institutional investors. 14.9% of Eton Pharmaceuticals shares are held by company insiders. Comparatively, 33.1% of XBiotech shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
In the previous week, Eton Pharmaceuticals had 8 more articles in the media than XBiotech. MarketBeat recorded 9 mentions for Eton Pharmaceuticals and 1 mentions for XBiotech. Eton Pharmaceuticals' average media sentiment score of 0.73 beat XBiotech's score of 0.24 indicating that Eton Pharmaceuticals is being referred to more favorably in the media.
Eton Pharmaceuticals has higher revenue and earnings than XBiotech. Eton Pharmaceuticals is trading at a lower price-to-earnings ratio than XBiotech, indicating that it is currently the more affordable of the two stocks.
Eton Pharmaceuticals presently has a consensus target price of $24.00, indicating a potential upside of 61.83%. Given Eton Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Eton Pharmaceuticals is more favorable than XBiotech.
XBiotech received 222 more outperform votes than Eton Pharmaceuticals when rated by MarketBeat users. Likewise, 69.98% of users gave XBiotech an outperform vote while only 65.07% of users gave Eton Pharmaceuticals an outperform vote.
Summary
XBiotech beats Eton Pharmaceuticals on 10 of the 19 factors compared between the two stocks.
Get XBiotech News Delivered to You Automatically
Sign up to receive the latest news and ratings for XBIT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
XBiotech Competitors List
Related Companies and Tools
This page (NASDAQ:XBIT) was last updated on 3/4/2025 by MarketBeat.com Staff
